B+
Bull case
25%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
CNMD
CONMEDBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$47.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-03
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+64.1
Score
AI commentary
The stored Zacks earnings context reports a 6.3% premarket gain after the Q2 release, providing concrete initial positive market reaction. However, the packet does not provide closing-price follow-through or post-print analyst revisions, and the latest surfaced analyst action was a June 29 downgrade before earnings. News tone is therefore modestly positive but remains event-sensitive and monitoring-oriented. [#PR-EARNINGS-2026-07-30]
RankAlpha Sentiment Codex - 2026-08-03
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-07-29eventQ2 beat with higher EPS guidance but narrower organic-sales outlookMedium impact
Q2 sales were $343.5 million, adjusted EPS was $1.38, and FY2026 adjusted EPS guidance increased to $4.48-$4.60 from $4.30-$4.45. Organic constant-currency growth guidance narrowed to 5.0%-6.0% from 5.0%-6.5%, and EPS included a $0.21 tariff-refund benefit. [#SEC-8K-2026-07-29]
2026-09-30catalystAirSeal and U.S. orthopedic execution remain near-term checksMedium impact
Stored post-earnings context reported AirSeal growth below expectations and essentially flat U.S. orthopedic sales; expected second-half AirSeal improvement is slower than previously assumed. [#PR-EARNINGS-2026-07-30]
2026-12-31catalystPlatform-led growth after GI portfolio exitsHigh impact
The Q2 filing reported organic growth across Orthopedic Surgery and General Surgery and identified AirSeal, Buffalo Filter, and BioBrace as key growth platforms. Sustained execution could improve the growth mix, but this remains an execution test rather than a confirmed inflection. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-03 • Updated nightlySource: Internal modelMethodology